These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 2850923)

  • 1. Buprenorphine is a potent kappa-opioid receptor antagonist in pigeons and mice.
    Leander JD
    Eur J Pharmacol; 1988 Jul; 151(3):457-61. PubMed ID: 2850923
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Buprenorphine blocks epsilon- and micro-opioid receptor-mediated antinociception in the mouse.
    Mizoguchi H; Spaulding A; Leitermann R; Wu HE; Nagase H; Tseng LF
    J Pharmacol Exp Ther; 2003 Jul; 306(1):394-400. PubMed ID: 12721333
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of beta-funaltrexamine to determine mu opioid receptor involvement in the analgesic activity of various opioid ligands.
    Zimmerman DM; Leander JD; Reel JK; Hynes MD
    J Pharmacol Exp Ther; 1987 May; 241(2):374-8. PubMed ID: 3033213
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of kappa-agonist on the antinociception and locomotor enhancing action induced by morphine in mice.
    Narita M; Takahashi Y; Takamori K; Funada M; Suzuki T; Misawa M; Nagase H
    Jpn J Pharmacol; 1993 May; 62(1):15-24. PubMed ID: 8393497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Mu antagonist and kappa agonist properties of beta-funaltrexamine (beta-FNA) in vivo: long-lasting spinal analgesia in mice.
    Qi JA; Heyman JS; Sheldon RJ; Koslo RJ; Porreca F
    J Pharmacol Exp Ther; 1990 Mar; 252(3):1006-11. PubMed ID: 2156986
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Antagonism of phosphoramidon-induced antinociception in mice by mu- but not kappa-opioid receptor blockers.
    Pruhs RJ; Peña RT; Quock RM
    Life Sci; 2007 Apr; 80(19):1816-20. PubMed ID: 17379253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Kappa-opioid receptor-mediated antinociception in the rat. II. Supraspinal in addition to spinal sites of action.
    Millan MJ; Członkowski A; Lipkowski A; Herz A
    J Pharmacol Exp Ther; 1989 Oct; 251(1):342-50. PubMed ID: 2571723
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological characterization of buprenorphine, a mixed agonist-antagonist with kappa 3 analgesia.
    Pick CG; Peter Y; Schreiber S; Weizman R
    Brain Res; 1997 Jan; 744(1):41-6. PubMed ID: 9030411
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Kappa antagonist properties of buprenorphine in the shock titration procedure.
    Negus SS; Dykstra LA
    Eur J Pharmacol; 1988 Oct; 156(1):77-86. PubMed ID: 2850212
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of differential modulation of mu-, delta- and kappa-opioid systems on bicuculline-induced convulsions in the mouse.
    Yajima Y; Narita M; Takahashi-Nakano Y; Misawa M; Nagase H; Mizoguchi H; Tseng LF; Suzuki T
    Brain Res; 2000 Apr; 862(1-2):120-6. PubMed ID: 10799676
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Kappa opioid antagonist effects of the novel kappa antagonist 5'-guanidinonaltrindole (GNTI) in an assay of schedule-controlled behavior in rhesus monkeys.
    Negus SS; Mello NK; Linsenmayer DC; Jones RM; Portoghese PS
    Psychopharmacology (Berl); 2002 Oct; 163(3-4):412-9. PubMed ID: 12373442
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thienorphine: receptor binding and behavioral effects in rhesus monkeys.
    Li JX; Becker GL; Traynor JR; Gong ZH; France CP
    J Pharmacol Exp Ther; 2007 Apr; 321(1):227-36. PubMed ID: 17220427
    [TBL] [Abstract][Full Text] [Related]  

  • 13. ATP-gated K(+) channel openers enhance opioid antinociception: indirect evidence for the release of endogenous opioid peptides.
    Lohmann AB; Welch SP
    Eur J Pharmacol; 1999 Dec; 385(2-3):119-27. PubMed ID: 10607867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. beta-Funaltrexamine antagonizes the analgesic effects of mu and kappa agonists in the formalin test.
    Abbott FV
    Pharmacol Biochem Behav; 1990 Dec; 37(4):713-6. PubMed ID: 1965514
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal by beta-funaltrexamine of the antinociceptive effect of opioid agonists in the rat.
    Hayes AG; Skingle M; Tyers MB
    Br J Pharmacol; 1986 Aug; 88(4):867-72. PubMed ID: 3017495
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Delta opioid antagonist effects of buprenorphine in rhesus monkeys.
    Negus SS; Bidlack JM; Mello NK; Furness MS; Rice KC; Brandt MR
    Behav Pharmacol; 2002 Nov; 13(7):557-70. PubMed ID: 12409994
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Blockade of mu-opioid receptor-mediated G-protein activation and antinociception by TRK-820 in mice.
    Mizoguchi H; Hung KC; Leitermann R; Narita M; Nagase H; Suzuki T; Tseng LF
    Eur J Pharmacol; 2003 Feb; 461(1):35-9. PubMed ID: 12568913
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gastric effects of mu-, delta- and kappa-opioid receptor agonists on brainstem unitary responses in the neonatal rat.
    Yuan CS
    Eur J Pharmacol; 1996 Oct; 314(1-2):27-32. PubMed ID: 8957215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Different roles of mu-, delta- and kappa-opioid receptors in ethanol-associated place preference in rats exposed to conditioned fear stress.
    Matsuzawa S; Suzuki T; Misawa M; Nagase H
    Eur J Pharmacol; 1999 Feb; 368(1):9-16. PubMed ID: 10096764
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of mu- and kappa-opioid receptors in cocaine-induced conditioned place preference.
    Suzuki T; Shiozaki Y; Masukawa Y; Misawa M; Nagase H
    Jpn J Pharmacol; 1992 Apr; 58(4):435-42. PubMed ID: 1328733
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.